Search Novartis.ca
Go
Français
Novartis.ca Home
Products
Pharmaceuticals
CIBA Vision
Animal Health
Over the Counter
Infant and Baby
Medical Nutrition
Diseases and Conditions
About Novartis
Investor Relations
News Centre
Careers
Corporate Citizenship
A through Z
Women's Health
Men's Health
Senior Health
For Parents
For Caregivers
Eye Health
Our Businesses
Research and Development
Management
F.A.Q.
Corporate Publications
Media Releases
Media Resources
Media Contact
Ranking and Articles
Our Values
Access to Excellence
Career Opportunities
Human Resources Policies
Health, Safety, & Environment
Our Stakeholders
In the Community
Pharmaceuticals - General Medicines
Pharmaceuticals - Specialty Medicines
Consumer Health
Canadian Media Releases
In Products
In Career Development
In People
Community Investment Donations Program
Academic Support
Product Donations
Community Partnership Day
[ Larger font size ]
[ Smaler font size ]
[ Printer friendly view ]
[ Select Country ]
[ Show Help page]
[ Contact us ]
Important Tegretol Information
For Healthcare Professionals
Important Sebivo Information
For Healthcare Professionals
For Sebivo Patients
Important Exjade Information
For Healthcare Professionals
For Exjade Patients
Important Prexige Information
For Healthcare Professionals
For Prexige Patients
Products
|
Phamaceutical Best Sellers
Products
Pharmaceuticals
CIBA Vision
Animal Health
Over the Counter
Infant and Baby
Medical Nutrition
Pharmaceutical Best Sellers: Top 5 Products in 2004
Diovan®
Diovan Prescribing Information
Diovan Patient Information
Clozaril®
Clozaril Prescribing Information
Clozaril Patient Information
Gleevec®
Gleevec Prescribing Information
Gleevec Patient Information
Neoral®
Neoral Prescribing Information
Neoral Patient Information
Visudyne
®
Visudyne Prescribing Information
Visudyne Patient Information
Back to the top
Share Information
Ride for the Cure!
Read our blog
Latest news
Novartis wins the 2007 Belleau-Nickerson Award for the cancer drug Gleevec
Aclasta* receives Health Canada approval as first and only once-yearly treatment for women with postmenopausal osteoporosis
Diseases and conditions
Top Employer
Printer friendly version
Novartis.com
|
Novartis.ca
|
Contact
|
Site Map
|
Help
|
Legal Disclaimer
|
Privacy Policy
© Novartis Pharmaceuticals Canada Inc. 2007 All Rights Reserved.
